Noah Davidsohn: Engineering Longevity at the Genetic Level

What if aging is not a collection of diseases, but a system-level failure we can intervene in?In this episode of Galaxy Balance, Cory Smith sits down with Noah Davidsohn, co-founder and CSO of Rejuvenate Bio, to explore a new approach to longevity rooted in gene therapy and systems biology.Noah’s work focuses on treating aging at its source by rebalancing key biological pathways across the body. Instead of targeting one disease at a time, his team is developing combination gene therapies designed to improve function across multiple organs simultaneously.Rejuvenate Bio is currently raising on Wefunder. This is a rare opportunity to invest in a scaling biotech on the same terms as their VC partners. If our conversation resonated with you, this is your chance to join what Dr. Noah Davidsohn is building. Learn more and invest at wefunder.com/rejuvenatebio00:00 - Replacing organs to reverse aging: science fiction or imminent reality00:34 - Welcome to Galaxy Balance: exploring biology and AI frontiers01:01 - Noah Davidson’s background and mission at Rejuvenate Bio01:57 - Reprogramming biological systems for systemic healthspan extension02:41 - The influence of sci-fi on Noah’s interest in space and longevity03:38 - Space exploration's crossover with biological resilience05:25 - The societal impact of science fiction on technological progress07:55 - Addressing dystopian themes in modern sci-fi and their societal reflection08:16 - The absence of longevity-focused sci-fi and Noah’s motivation09:12 - Personal story: pet dog inspired Noah’s longevity work10:33 - Origin of Rejuvenate Bio and its mission to treat aging11:57 - Combining gene therapies targeting multiple age-related diseases13:44 - The potential and limitations of epigenetic partial reprogramming14:14 - Upcoming clinical trials and safety considerations for gene therapy16:01 - Cyclic gene therapy and risks of permanent expression17:43 - Inducible gene expression systems: safety and practical considerations21:19 - Systemic, liver-targeted gene therapies: permanent vs. transient22:33 - Strategies for pet therapies and expanding to human applications25:47 - Manufacturing innovations reducing costs for wide-scale treatment27:12 - Prophylactic use of gene therapies in pets and humans29:08 - Targeting multiple diseases with a single systemic therapy30:40 - Breeds at risk for mitral valve disease and targeted therapy efforts33:42 - Disease-modifying treatments for fibrosis and heart failure36:48 - How AAV vector delivery works and safety measures in tissue targeting42:47 - Regulatory pathways for animal therapies and translational relevance44:22 - Challenges in funding and VC environment for longevity startups45:45 - The strategy of using animal models as a bridge to human therapies50:05 - Future scientific directions: partial reprogramming and cell replacement tech52:37 - The concept of longevity escape velocity and current progress53:44 - Personal longevity practices: exercise, diet, sleep, stress management55:27 - The role of biometric feedback devices in health monitoring56:54 - Emerging modalities and innovative approaches in anti-aging research58:24 - The ship of Theseus analogy for cell and tissue replacement59:37 - Philosophical questions about consciousness and identity in aging1:00:43 - Recommended sci-fi books for longevity and biotech enthusiasts1:01:39 - Career advice for aspiring scientists and interdisciplinary innovation1:02:45 - Wrap-up and best wishes for ongoing longevity breakthroughs